लिनेज़ोलिड के इंटरैक्शन

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Taking, or within 14 days of stopping, a monoamine oxidase inhibitor (MAOI) [see Drug Interactions (7) ] . (एटोमोक्सेटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS IOPIDINE 1% Ophthalmic Solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. (एप्राक्लोनिडिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (एम्फेटामाइन और डेक्सट्रोएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.3) ] . (ऑक्सीकोडोन लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.2)]. (ऑक्सीकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (ओन्डैनसेट्रॉन लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (कार्बामाज़ेपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. (कार्बिडोपा लेबल, निषेध (कॉन्ट्राइंडिकेशन))

DUOPA is contraindicated in patients who are currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. (कार्बिडोपा और लेवोडोपा लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…because deaths have been reported in this age group [see Warnings and Precautions (5.1)]. patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Carbinoxamine Maleate Extended-Release Oral Suspension [see Warnings and Precautions (5.4)]. patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)]. (कार्बिनोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ), Drug Interactions ( 7 )]. (कोडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. (ग्रैनिसेट्रॉन लेबल, चेतावनियां और सावधानियां)

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. (ज़िप्रासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Taking monoamine oxidase inhibitors (MAOIs). (टेट्राबेनाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…suspected paralytic ileus [see Warnings and Precautions (5.12) ] Hypersensitivity to tapentadol (e.g., anaphylaxis, angioedema) or to any other ingredients of the product [see Adverse Reactions (6.2) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Drug Interactions (7) ] Significant respiratory depression ( 4 ) (टेपेंटाडोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.16) ] Hypersensitivity to tramadol (e.g., anaphylaxis) [see Warnings and Precautions (5.17) , Adverse Reactions (6) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days [see Drug Interactions (7) ] Children younger than 12 years of age. (ट्रामाडोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days [see Drug Interactions (7) ]. (ट्रामाडोल और पैरासिटामोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Intervention: RALDESY is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Contraindications (4) , Dosage and Administration ( 2.3 , 2.4) , and Warnings and Precautions (5.2) ]. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Need for Emergency Treatment with Contraindicated Drugs If in the absence of therapeutic alternatives emergency treatment with a contraindicated product (e.g., linezolid, intravenous methylene blue, direct-acting sympathomimetic drugs such as epinephrine) becomes necessary and cannot be delayed, discontinue tranylcypromine sulfate tablets as soon as possible… (ट्रैनिलसाइप्रोमिन लेबल, चेतावनियां और सावधानियां)

During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result. (डाइएथिलप्रोपियॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid use of diphenoxylate hydrochloride and atropine sulfate in patients who take MAOIs and monitor for signs and symptoms of hypertensive crisis (headache, hyperthermia, hypertension). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Antihistamines are also contraindicated in the following conditions: Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure Monoamine oxidase inhibitor therapy (See Drug Interaction section) (डेक्सक्लोरफेनिरामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ]. (डेक्सट्रोएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (डेक्सट्रोमेथॉर्फन लेबल, चेतावनियां)

Use with an MAOI or within 14 days of stopping an MAOI. (डेक्सट्रोमेथॉर्फन और क्विनिडिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions ( 7.1 )] . (डेक्समिथाइलफेनिडेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [ see Drug Interactions… (डॉक्सीलामिन और पाइरिडोक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Taking monoamine oxidase inhibitors (MAOIs). (ड्यूटेट्राबेनाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA. (ड्रॉक्सीडोपा लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors (MAOIs) MAOI (e.g., phenelzine, tranylcypromine, linezolid) interactions with opioids may manifest as serotonin syndrome [see PRECAUTIONS; Drug Interactions ] or opioid toxicity (e.g., respiratory depression, coma [see WARNINGS ]). (नालबुफिन लेबल, दवाओं के इंटरैक्शन)

Starting CONTRAVE in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated [see Dosage and Administration (2.4) , Drug Interactions (7.1) ] Known allergy to bupropion, naltrexone or any other component of CONTRAVE. (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Severe hyperthermia and seizures, sometimes fatal, have been reported in association with the combined use of tricyclic antidepressants and MAOIs. (नेफाज़ोडोन लेबल, चेतावनियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (पेंटाज़ोसिन और नालोक्सोन लेबल, सावधानियां)

Concomitant Use of DEMEROL Injection with Monoamine Oxidase (MAO) Inhibitors Concomitant use of DEMEROL Injection with monoamine oxidase (MAO) inhibitors can result in coma, severe respiratory depression, cyanosis, and hypotension. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

…respiratory depression ( see WARNINGS ). acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment ( see WARNINGS ). concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days ( see WARNINGS ). known or suspected gastrointestinal obstruction, including paralytic ileus ( see WARNINGS… (पैरासिटामोल और कोडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (पैलोनोसेट्रॉन लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within 14 days [ see Warnings and Precautions (5.16) , Drug Interactions (7.6) ]. (प्रोमेथाज़िन और कोडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (see PRECAUTIONS – Drug Interactions ). (प्रोमेथाज़िन और डेक्सट्रोमेथॉर्फन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release… (फेंटरमिन और टोपिरामेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (फेंटानिल लेबल, चेतावनियां और सावधानियां)

…coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension, pulmonary hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other… (फेनडाइमेट्राज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Monoamine Oxidase Inhibitors Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. (लिनेज़ोलिड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome. (बस्पिरोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. (बेंज़फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…Precautions (5.2) ] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [ see Warnings and Precautions (5.5) ] • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [ see Warnings and Precautions (5.7), Drug Interactions (7) ] • Known or suspected gastrointestinal obstruction,… (बेलाडोना और ओपियम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…Precautions ( 5.2 )] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions ( 5.10 )] • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.11 ), Drug Interactions ( 7 )] • Known or suspected gastrointestinal obstruction,… (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (ब्यूटॉर्फेनॉल लेबल, सावधानियां)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Examples: phenelzine, tranylcypromine, linezolid Muscle Relaxants Clinical Impact: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.8), Warnings and Precautions (5.4), and Drug Interactions (7.6)] . (ब्यूप्रोपियॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Avoid use of MAO inhibitors or linezolid with midodrine. (मिडोड्रिन लेबल, दवाओं के इंटरैक्शन)

CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (मिथाइलडोपा लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ]. (मिथाइलफेनिडेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome. (मिथाइलीन ब्लू लेबल, दवाओं के इंटरैक्शन)

REMERON/REMERONSolTab is contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . (मिर्टाज़ापिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (मेटाक्सालोन लेबल, दवाओं के इंटरैक्शन)

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, avoid use in patients with hypertension or in patients taking monoamine oxidase inhibitors [see Drug Interactions ( 7.1 )] . (मेटोक्लोप्रामाइड लेबल, चेतावनियां और सावधानियां)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (मेथएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (मेथाडोन लेबल, चेतावनियां और सावधानियां)

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.9 ) and Drug Interactions ( 7 )]. (मॉर्फिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (रासाजिलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (रेमिफेंटानिल लेबल, चेतावनियां और सावधानियां)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (लिथियम लेबल, चेतावनियां और सावधानियां)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1) ] . (लिसडेक्सएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (लेवॉर्फेनॉल लेबल, सावधानियां)

INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor. (लेवोडोपा लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (वाल्बेनाज़िन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Qelbree is contraindicated in patients: receiving concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis [see Drug Interactions (7.1) ] . receiving concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic… (विलोक्साज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Starting TRINTELLIX in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2) ] . (वोर्टियोक्सेटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of a MAO inhibitor. (साइक्लोबेंज़ाप्रिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Monoamine oxidase inhibitor therapy (See DRUG INTERACTIONS ). (साइप्रोहेप्टाडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

सेंट जॉन्स वॉर्ट को एंटीडिप्रेसेंट और अन्य सेरोटोनर्जिक दवाओं के साथ लेने से सेरोटोनिन सिंड्रोम का जोखिम बढ़ता है। (NCCIH, St. John's Wort)

MAO Inhibitors ZELAPAR is contraindicated for concomitant use with other drugs in the MAOI class or other drugs that are potent inhibitors of monoamine oxidase (including linezolid, an oxazolidinone antibacterial, which also has reversible nonselective MAO inhibition activity) because of the increased risk for hypertensive crisis [see Contraindications (4) and… (सेलेजिलिन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.3) ] . (हाइड्रोकोडोन लेबल, दवाओं के इंटरैक्शन)

If urgent use of an opioid is necessary with MAOIs such as phenelzine, tranylcypromine, linezolid, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, दवाओं के इंटरैक्शन)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, दवाओं के इंटरैक्शन)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.3 )]. (हाइड्रोमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Concomitant Use with MAO Inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (आइसोफ्लुरेन लेबल, दवाओं के इंटरैक्शन)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression. (एस्टाज़ोलम लेबल, दवाओं के इंटरैक्शन)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (कार्वेडिलोल लेबल, दवाओं के इंटरैक्शन)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monoamine-oxidase inhibitors: Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors. (कोकेन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines. (क्लेमास्टिन लेबल, दवाओं के इंटरैक्शन)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (क्लोनाज़ेपाम लेबल, दवाओं के इंटरैक्शन)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (क्लोराज़ेपेट लेबल, दवाओं के इंटरैक्शन)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (क्लोरोप्रोकेन लेबल, सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. (डाइफेनहाइड्रामिन लेबल, दवाओं के इंटरैक्शन)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (डायज़ेपाम लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance,… (ड्रोपेरिडोल लेबल, चेतावनियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors (MAOI) Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. (प्रोमेथाज़िन लेबल, दवाओं के इंटरैक्शन)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (ब्यूटाल्बिटल और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors may result in increased hypotension. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors may result in increased hypotension. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (मेटोप्रोलोल लेबल, दवाओं के इंटरैक्शन)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (मेपिवाकेन लेबल, चेतावनियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (लिडोकेन लेबल, दवाओं के इंटरैक्शन)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (सक्सिनिलकोलिन लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (सेवोफ्लुरेन लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Drug Interactions MAO inhibitors should be used with caution in patients receiving hydralazine. (हाइड्रालाज़िन लेबल, दवाओं के इंटरैक्शन)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

It is theoretically possible, therefore, that the combination of Entacapone Tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (एंटाकैपोन लेबल, चेतावनियां)

Commonly used serotonergic agents include serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone, serotonin 5-HT1 receptor agonists (triptans), and opioids, including meperidine. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

…Catheter-Related Bloodstream Infections, Including Those With Catheter-Site Infections An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16.0%); odds ratio 1.426, 95% CI 0.970, 2.098]. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

It is theoretically possible, therefore, that the combination of Tolcapone tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (टोलकैपोन लेबल, चेतावनियां)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

…Catheter-Related Bloodstream Infections, Including Those With Catheter-Site Infections An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16.0%); odds ratio 1.426, 95% CI… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

Drug Interactions Since the chemical structure of difenoxin hydrochloride is similar to meperidine hydrochloride, the concurrent use of MOTOFEN ® with monoamine oxidase inhibitors may, in theory, precipitate a hypertensive crisis. (डाइफेनॉक्सिन और एट्रोपिन लेबल, दवाओं के इंटरैक्शन)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (प्रोप्रानोलोल लेबल, दवाओं के इंटरैक्शन)

…Patients With Catheter-Related Bloodstream Infections, Including Those With Catheter-Site Infections An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16.0%); odds ratio 1.426,… (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)